Literature DB >> 6118518

Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again.

G Danan, D Pessayre, D Larrey, J P Benhamou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6118518     DOI： 10.1016/s0140-6736(81)91262-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

Review 2.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

3.  Chemotherapeutic agents in pulmonary tuberculosis with special reference to isoniazid-ethambutol continuation therapy.

Authors:  A W Lees
Journal:  Ir J Med Sci       Date:  1985-05       Impact factor: 1.568

4.  Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.

Authors:  Tina Papastavros; Lisa R Dolovich; Anne Holbrook; Lori Whitehead; Mark Loeb
Journal:  CMAJ       Date:  2002-07-23       Impact factor: 8.262

5.  Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review.

Authors:  Miranda W Langendam; Edine W Tiemersma; Marieke J van der Werf; Andreas Sandgren
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.